Skip to content

Lobbying by Bristol Myers Squibb Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Bristol Myers Squibb Canada

Meetings this Parliament
20
With MPs
2
Since Nov 2021
20
Active registrations
1

Most recent reported meeting: Oct 7, 2026.

Bills they've lobbied on

Named in their own descriptions of meetings or of their registration. Their words are quoted below each bill.

Who they meet

Since the current Parliament opened.

MPs

Institutions

  • Health Canada (HC)12
  • Innovation, Science and Economic Development Canada (ISED)11
  • Treasury Board Of Canada Secretariat (TBS)4
  • Finance Canada (FIN)4
  • Privy Council Office (PCO)3
  • Intergovernmental Affairs Secretariat (IGA)3
  • House of Commons2
  • Fisheries and Oceans Canada (DFO)2

Registrations in effect

In-house (corporation) In effect since Oct 7, 2026

Filed by Massimiliano Magnelli, President and General Manager

Lobbyists

  • Christopher Eric Praught · National Policy, Public, and Government Affairs Lead Former public office holder

    Formerly Senior Policy and Regional Affairs Advisor, Minister's Office, Natural Resources Canada (2012–2015)

    Formerly Director of Policy, Minister's Office, Public Works and Government Services Canada (2009–2012)

    Formerly Policy Advisor, Minister's Office, Employment and Social Development Canada- Labour Program (2009–2009)

    Formerly Senior Special Assistant, Minister's Office, Western Economic Diversifacation (2007–2009)

  • Daphne Weatherby · Associate Director, Head, Corporate Affairs
  • Franck Chenu · Senior Director, Medical Affairs
  • Francois Villeneuve · Senior Director, Commercial
  • Heather O'Brien · Director, Strategy and Operations
  • Helen Trifonopoulos · Head of Market Access, Public Affairs and Patient Support Programs
  • Joel Roy · Legal Lead
  • Litsa Kouroumalis · Director, Compliance and Ethics
  • Mary Tzortzis · Director, Clinical Operations
  • Massimiliano Magnelli · President and General Manager
  • Richard Briand · Senior Director, Regulatory Affairs
  • Vivian Chen · Director, Finance

Institutions they may lobby: Canadian Institutes of Health Research (CIHR), Correctional Service of Canada (CSC), Federal Economic Development Agency for Northern Ontario, Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Research Council (NRC), Natural Resources Canada (NRCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (1)
  • Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

Registration 966197-14224-14. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Elaine Phillips (15), Massimiliano Magnelli (5).

  • Reported by Massimiliano Magnelli · In-house (corporation)

    • Nicholas Chesterley · Director General, Finance Canada (FIN)
    • Nyssa McLeod · Director, Finance Canada (FIN)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Massimiliano Magnelli · In-house (corporation)

    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Massimiliano Magnelli · In-house (corporation)

    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mark Schaan · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Kaili Levesque · Associate Deputy Minister, Federal Economic Development Agency for Southern Ontario (FedDev)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Massimiliano Magnelli · In-house (corporation)

    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Massimiliano Magnelli · In-house (corporation)

    • Justine Frame · Policy Advisor, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Justine Frame · Policy Advisor, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Abla Hanna · Director of Operations, Natural Resources Canada (NRCan)
    • Isabelle Mondou · Deputy Clerk, Privy Council Office (PCO)
    • Greg Reade · Assistant Secretary to the Cabinet, Privy Council Office (PCO)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Jade Mallette · Chief of Staff to the Minister of Health, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Marie-Pier Fontaine · Deputy Director, Privy Council Office (PCO)
    • Kathleen McLellan · Senior Policy Advisor, Privy Council Office (PCO)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Marjorie Michel · Minister of Health
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
    and 9 more
    • Supriya Sharma · Acting ADM, Innovation, Science and Economic Development Canada (ISED)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Koshar · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Fatoumata Bah · Policy Advisor, Health Canada (HC)
    • Scott Lohnes · Senior Advisor, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 6 more
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Kaili Levesque · ADM, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    and 6 more
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    and 3 more
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 5 more
    • Celia Lourenco · AADM, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Sara O'Connor · AADM, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Maggie Chi · Member of Parliament
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    and 8 more
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Annahat Kochar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    and 2 more
    • Daniel MacDonald · Director General, Health Canada (HC)
    • Brent Lawlor · Acting Director, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Justine Frame · Policy Advisor, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Reported by Elaine Phillips · In-house (corporation)

    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.